DuraGraft is the 1st and only approved Endothelial Damage Inhibitor. It is a one-time intraoperative treatment of vascular grafts that preserves endothelial function and structure for the prevention of graft disease, thereby reducing graft failure rates and improving clinical outcomes.

DuraGraft treatment has been shown to significantly reduce major cardiac events such as repeat revascularization, myocardial infarction and MACE over five years plus post CABG. Learn more about DuraGraft.

Based on US Retrospective Study - more than 2000 CABG Patients

48%

Reduction in
Myocardial Infarction
p=0.0001

53%

Reduction in
Repeat Revascularization
p=0.02

*Manuscript in preparation

18%

Reduction in
MACE
p=0.02